Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 11:9:2050313X211034926.
doi: 10.1177/2050313X211034926. eCollection 2021.

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Maruška Marovt  1 , Pij B Marko  1
Affiliations
Case Reports

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Maruška Marovt et al. SAGE Open Med Case Rep. .

Abstract

Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none is accepted as being effective in general. Apremilast is a small molecule inhibitor of phosphodiesterase 4 approved for the treatment of plaque psoriasis and psoriatic arthritis. We report three cases of palmoplantar pustulosis treated with apremilast monotherapy. Our three cases, as well as previous reports, demonstrate the potential for apremilast to be beneficial for a subset of patients with palmoplantar pustulosis or palmoplantar pustular psoriasis.

Keywords: Psoriasis; apremilast; therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.M. served as a paid speaker and/or advisory board member for AbbVie, Celgene, Amgen, Janssen, Eli Lilly, L’Oreal and Novartis. The other author declares no conflicts of interest.

Figures

Figure 1.
Figure 1.
Hands and foot of a first case 10 days after treatment with topical corticosteroids and acitretin (left) and hands and foot of a first case 2 years after apremilast therapy (right).
Figure 2.
Figure 2.
Hands and feet of a second patient 1.5 year after apremilast therapy (left) and hands of a third case before apremilast therapy (upper right) and 3 months after apremilast therapy (lower right).
See this image and copyright information in PMC

References

    1. Edwards CJ, Blanco FJ, Crowley J, et al.. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016; 75(6): 1065–1073. - PMC - PubMed
    1. Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol 2020; 21(3): 355–370. - PMC - PubMed
    1. Bissonnette R, Haydey R, Rosoph LA, et al.. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol 2018; 32(3): 403–410. - PubMed
    1. Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol 2017; 42(4): 471–473. - PubMed
    1. Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol 2019; 46(1): e29–e30. - PubMed

Publication types

LinkOut - more resources